Ann: Pause in Trading, page-48

I'm getting the feeling the larger names have gone cold on msb after the FDA CRL and Novartis pulling out, and are happy to sit on the sidelines and wait until the outcome of the next FDA submission to see if msb can get over the final hurdle before committing to a partnership.

Novartis rushed in and lost $50m to gain nothing out of the deal, I know that's peanuts to these types of companies but I doubt others will be too keen to do the same without seeing the proof that msb can overcome the FDA.

The way I see this playing out is Ryoncil resubmission first and foremost, if successful then partnership interest will build on the other programs. msb is on the clock, and the big pharmas know this. I'd love to be proven wrong by a left-field announcement in the coming months, but msb have everything to prove, everything to lose, and the big pharmas have nothing but time. Realistically looking at the resulting carnage after last time, if msb fumbles the FDA outcome again, do you think they'll be able to keep getting interested parties to fund the other programs?